Quote:

---

You can’t read this article and not walk away without the impression the medical community is throwing darts at it, typically with multiple agent regimens.

---

Quote:

---

One of the main obstacles in achieving efficacy with ICIs is the limited infiltration of immune cells in the TME. In the case of MSS CRC, there is a lack of sufficient immune cells available for activation by ICIs in the TME.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770832/

---

Leronlimab boosts CD8+ T cells (immune cells) while stripping away the tumors defenses that keep those immune cells away.

As a side note a nice commentary on CCR5/CCL5 and CRC -

https://jitc.bmj.com/content/12/5/e008722